Dendritic cells dictate the responsiveness to PD-L1 blockade in cancer

被引：0

作者：

Mayoux, M. ^{[1
]}

Roller, A. ^{[2
]}

Pulko, V ^{[1
]}

Chen, S. ^{[1
]}

Fransen, M. ^{[3
]}

Kowanetz, M. ^{[4
]}

Rommel, K. ^{[1
]}

Matos, I ^{[1
]}

Colombetti, S. ^{[1
]}

Belousov, A. ^{[5
]}

Karanikas, V ^{[1
]}

Hegde, P. ^{[4
]}

Chen, D. ^{[4
]}

Mellman, I ^{[4
]}

Umana, P. ^{[1
]}

Perro, M. ^{[1
]}

Ossendorp, F. ^{[3
]}

Klein, C. ^{[1
]}

Xu, W. ^{[1
]}

机构：

[1] Roche Innovat Ctr Zurich, Schlieren, Switzerland

[2] Roche Innovat Ctr Basel, Basel, Switzerland

[3] Leiden Univ, Med Ctr, Leiden, Netherlands

[4] Genentech Inc, San Francisco, CA USA

[5] Roche Innovat Ctr Munich, Penzberg, Germany

来源：

EUROPEAN JOURNAL OF IMMUNOLOGY | 2018年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

T-40

引用

页码：22 / 23

页数：2

共 50 条

[31] Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, Joy
Hodgins, Jonathan J.
Marathe, Malvika
Nicolai, Chris J.
Bourgeois-Daigneault, Marie-Claude
Trevino, Troy N.
Azimi, Camillia S.
Scheer, Amit K.
Randolph, Haley E.
Thompson, Thornton W.
Zhang, Lily
Iannello, Alexandre
Mathur, Nikhita
Jardine, Karen E.
Kirn, Georgia A.
Bell, John C.
McBurney, Michael W.
Raulet, David H.
Ardolino, Michele
JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (10): : 4654 - 4668
[32] PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Wang, Yumeng
Li, Guiling
FRONTIERS OF MEDICINE, 2019, 13 (04) : 438 - 450
[33] PD-1/PD-L1 Blockade Accelerates the Progression of Atherosclerosis in Cancer Patients
Dong, Mei
Yu, Ting
Tse, Gary
Lin, Zerun
Lin, Chen
Zhang, Nan
Wang, Rujian
Liu, Tong
Zhong, Lin
CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (03) : 1 - 20
[34] PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Yumeng Wang
Guiling Li
Frontiers of Medicine, 2019, 13 : 438 - 450
[35] Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer
Noguchi, Emi
Shien, Tadahiko
Iwata, Hiroji
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 321 - 332
[36] Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells
Matrone, N.
Napolitano, S.
Belli, V.
Barra, G.
Giunta, E. F.
De Falco, V.
Terminiello, M.
Vitiello, P. P.
Ciardiello, D.
Turano, M.
Furia, M.
Muddassir, A. S.
Kopetz, S.
Martinelli, E.
Ciardiello, F.
Troiani, T.
ANNALS OF ONCOLOGY, 2019, 30
[37] PD-1–PD-L1 axis: efficient checkpoint blockade against cancer
Alessia Errico
Nature Reviews Clinical Oncology, 2015, 12 : 63 - 63
[38] PD-L1 blockade and upregulation in an ovarian cancer treatment model
Grabosch, Shannon
Zhang, Lixin
Zeng, Feitianzhi
Mony, Jyothi
Ma, Tianzhou
Tseng, George
Edwards, Robert
Vlad, Anda
JOURNAL OF IMMUNOLOGY, 2015, 194
[39] PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, Andreas D.
Taran, Florin-Andrei
Wallwiener, Markus
Walter, Christina B.
Kraemer, Bernhard
Grischke, Eva-Maria
Brucker, Sara Y.
BREAST CARE, 2016, 11 (06) : 385 - 390
[40] Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
Wang, Qiaohong
Wu, Xia
INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 46 : 210 - 219

← 1 2 3 4 5 →